Expected outcomes

 
  • Appropriate DIKI, DILI and DIVI biomarkers and methods qualified by the EMA and FDA for use in medical product development
  • Database for human safety biomarkers with a detailed characterization of clinical, individual and drug-specific factors in the context of drug-induced toxicities and diseases.
  • Biobank of human material, obtained at different time points from patients enrolled in the clinical trials run by the consortium, to support future qualification of new biomarkers.
 
Expected outcomes